Is Pacific Biosciences of California (PACB) overvalued? · rev $38.4M
Pacific Biosciences of California (PACB) is a medical devices company listed on US.
This page asks whether Pacific Biosciences of California (PACB) looks expensive on cached numbers — not a short thesis.
Latest reported PACB revenue for 2025-09-30 was $38.4M. Net income was -$38.0M. Revenue was down 3.3% from 2025-06-30 to 2025-09-30. PACB currently screens at market cap $387.1M.
PACB currently screens at market cap $387.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PACB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PACB stock page for the full model, not this heading.
Not investment advice.